Critically important studies emerging from China suggest that for many patients who die of Covid-19, it may be their own immune system, rather than the virus itself, that deals the fatal blow. This is called a cytokine storm.

During a cytokine storm, an excessive immune response ravages healthy lung tissue, leading to acute respiratory distress and multi-organ failure. Untreated, cytokine storm syndrome is usually fatal. Patients in other studies who developed cytokine storm syndrome after viral triggers often ironically possessed subtle genetic immune defects resulting in the uncontrolled immune response.

Over the past two decades, much has been learned about the diagnosis and treatment of cytokine storm syndromes. On the front lines of the Covid-19 response, it is critical that medical professionals are aware of the syndrome and prepared to identify and treat it.

This act of preparation could help to significantly reduce the number of deaths from Covid-19. In treating cytokine storms brought about by other illnesses, like other viral infections and autoimmune diseases, death rates among patients suffering a cytokine storm have been reduced to as low as 27 percent.

Until vaccines for the novel coronavirus are available, likely a year or more from now, it is possible that millions of people may become infected around the globe. This is in part due to minimal early symptoms in up to 80 percent of those who become infected.

However, seemingly mild cases of Covid-19 can morph into more severe cases involving the lower lungs, and up to 20 percent of symptomatic novel coronavirus infected individuals require hospitalization, with 5 percent overall needing intensive care. Although individuals who are elderly or who have underlying chronic health problems are at a higher risk of mortality, younger previously healthy people have also succumbed to severe Covid-19

Cytokine storm syndromes go by many names, but they share the pathology of an overly active immune response that leads to frequently fatal multi-organ dysfunction syndrome (MODS). The risk factors for why some previously healthy individuals become deathly ill remain unknown. There are likely host factors, including genetic mutations that put individuals at higher risk. Until the risk factors are known, the medical community will need to treat those Covid-19 patients based solely on the severity of their disease.

How to screen for cytokine storm syndrome in sick patients
While novel and repurposed anti-viral therapies are being explored to treat Covid-19, those individuals with cytokine storm syndrome also require treatment of the overly active immune response. In these situations, an overactive immune response can be deadly. All Covid-19 patients sick enough for hospitalization should be given a cheap, quick, and readily available serum ferritin blood test. Indeed, elevated serum ferritin values have recently been reported in Chinese hospitalized patients with Covid-19. This is a good first screening tool for the possibility of a cytokine storm syndrome in sick patients with high fevers.

The question then remains how best to treat a cytokine storm syndrome once it is identified. The treating physician is often placed between a rock and a hard place. Corticosteroids can be powerfully broad immunosuppressive agents, and they are inexpensive and readily available throughout the world. However, it can be frightening for a physician to treat a severely ill, infected individual with such powerful and wide-ranging immune suppression.

We already have medicines for treating cytokine storm syndrome triggered by viruses
With the development of biologic therapies for a variety of rheumatic, oncologic, and other conditions, novel approaches to treating the immune response are now available. These highly-targeted medicines go after one or a few inflammatory molecules, including cytokines, without the general immune suppression affected by corticosteroids and other relatively non-selective immune suppressants.

Recently, a number of specific anti-cytokine approaches have proven effective in treating a variety of cytokine storm syndromes, including those triggered by viruses. These include drugs targeting interleukin-1 (IL-1), IL-6, IL-18, and interferon-gamma. While randomized trials will be needed to confirm which, if any, of these therapeutics will effectively treat Covid-19-infected patients with cytokine storm syndrome, IL-6 blockade has recently been reported to be in use in China with successful outcomes in some individuals receiving this as part of their treatment.

While working to prevent future outbreaks of deadly coronavirus infections with vaccine development and discovering new or re-purposed anti-viral medicines to treat the virus, we must also use all the knowledge at our disposal to treat those patients most at risk of dying – including from Covid-19-induced cytokine storms. For this to occur, the medical community must first be aware of the possibility, then make the diagnosis, and finally treat infected individuals with overly active immune responses that are harmful, if not fatal, left untreated. This should help save the lives of those unfortunate individuals at risk of Covid-19 induced cytokine storm syndrome.

Randy Q. Cron, MD, Ph.D., is a professor of pediatrics and medicine and director of the Division of Pediatric Rheumatology at the University of Alabama at Birmingham. In November 2019, he published Cytokine Storm Syndrome, the first dedicated textbook on cytokine storms.

  1. Winn Chatham, MD, is a professor of medicine, clinical immunology, and rheumatology; senior scientist at the Comprehensive Arthritis, Musculoskeletal, Bone and Autoimmunity Center (CAMBAC); and director of Rheumatology Clinical Services at the University of Alabama at Birmingham

The use of curcumin should be investigated in patients with severe flu symptoms and cytokine storm.

Curcumin blocks cytokine release, most importantly the key pro-inflammatory cytokines, interleukin-1, interleukin-6, and tumor necrosis factor-α. The suppression of cytokine release by curcumin correlates with clinical improvement in experimental models of disease conditions where a cytokine storm plays a significant role in mortality.

Leave a Reply

Your email address will not be published.

Clinical Trial & Our Product

Since health care & medicine is an industry, formulations are controlled through intellectual property rights denying easy access to common people and maintaining the buoyancy for the interest holders. Formula’s can be patented and that covers business interests that drive innovations these days.

So instead of conducting trials on the raw root, almost all companies promote clinically tested formulations of extracts to make it appear better then how the phytochemical was in its original state. Its like extracting an important organ from the body and then putting it on support system, expecting it to perform better in insolation then how it could perform when in it was in its natural form. The truth is, that the best way to consume a plant based medicine is in its raw form. Curcumin is one of the active ingredients in the root Curcuma Longa.

Since its more important to know what your food ate then what you ate, its important to know that the supplements you are using based on curcumin has curcumin from a gene modified variety of curcuma longa which suffers from an imbalance of every other mineral. You see a plant also behaves how a human body behaves when it is injected with steroids to gain muscle mass for body building purpose. The plants have higher levels of curcumin but all other secondary minerals found along curcumin in the plant get compromised as the plant can not feed all nutritions equally when it is designed to feed most of its nutrition towards developing higher levels of curcumin. It has severe side effects on the health of the plant and apparently on the people consuming such plants or extracts coming from these plants. However marketing and promotions have evolved to divert attention very wisely.

An extract of any herb can never be stored in its original state and hence needs base agents, preservatives which hardly leave it how it must be. We believe that access to medicine and healthcare is a basic right of every human and animal living on planet earth. Hence we do not first extract and then add preservatives or agents like pepperine to make the extract bio-available. This is the reason we never patent any of our products. We instead hand process the whole root we cultivate in our farms and share it with the people under different brand names for different health conditions based on the concentration of minerals present at testing. You can also buy the seed from us and cultivate it but it will certainly not be as potent as you get from us.

How potent is the active ingredient in the plant depends on the quality of seed, soil, water and environment. Our products work far better then most of the curcumin based supplements globally being used for Therapeutic benefits.

We do not intend to formulate or patent our products. So instead of choosing a supplement with an extract, choose wisely and go for the best and not the Cheapest.

All our products are cultivated, harvested, hand processed and distributed directly from our own farms to ensure that people who depend on our products for their acute and chronic problems get consistent supply of highest quality, ultra premium, medicinal grade, Non-GMO, Indigenous, Naturally enriched with curcumin, Wild Strand curcuma longa powder for therapeutic benefits. We cultivate this in the middle of a national park which happens to be the best breeding ground for Bengal tigers in India called Bandhavgarh.